Relief Therapeutics Holding SA
SIX:RLF
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/EBITDA
Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Valuation Scenarios
If EV/EBITDA returns to its Industry Average (8), the stock would be worth CHf-0.35 (133% downside from current price).
| Scenario | EV/EBITDA Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | -24 | CHf1.06 |
0%
|
| Industry Average | 8 | CHf-0.35 |
-133%
|
| Country Average | 12.7 | CHf-0.56 |
-153%
|
Forward EV/EBITDA
Today’s price vs future ebitda
Peer Comparison
| Market Cap | EV/EBITDA | P/E | ||||
|---|---|---|---|---|---|---|
| CH |
|
Relief Therapeutics Holding SA
SIX:RLF
|
437m CHF | -24 | -25.6 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | -194 446.1 | -160 127.7 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
354.5B USD | 14.1 | 84.7 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
186.5B USD | 14 | 24.2 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
164.9B USD | 12.2 | 19.4 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | -581 | -533.6 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
111.2B USD | 21.1 | 28.1 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
78.9B USD | 13 | 17.5 | |
| NL |
|
argenx SE
XBRU:ARGX
|
42B EUR | 41 | 38 | |
| AU |
|
CSL Ltd
ASX:CSL
|
62.3B AUD | 10.3 | 30.3 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | -66.6 | -61.8 |
Market Distribution
| Min | 0 |
| 30th Percentile | 9.2 |
| Median | 12.7 |
| 70th Percentile | 20.5 |
| Max | 1 129.6 |
Other Multiples
Relief Therapeutics Holding SA
Glance View
RELIEF THERAPEUTICS Holding AG is a clinical stage biotechnology company. The company is headquartered in Geneve, Geneve and currently employs 55 full-time employees. The company went IPO on 2011-09-19. The Company’s objective is to provide patients with therapeutic relief in serious diseases with high unmet medical need, as well as to focus on developing treatments for respiratory diseases. The company specializes in clinical-stage projects based on molecules of natural origin (peptides and proteins with a history of clinical use and either initial human activity with efficacy data or a strong scientific rationale. Its lead compound is RLF-100 (aviptadil), a synthetic human vasoactive intestinal peptide (VIP) with a multifaceted mode of action in respiratory indications. RLF-100 is being investigated in two placebo-controlled U.S. phase 2b/3 clinical trials in respiratory deficiency due to COVID-19. Its RLF-100 is also used for pulmonary sarcoidosis. The firm is also involved in the clinical development of RLF-100 that is in planning stage for other indications in acute and chronic lung diseases.
